Список литературы

Глава 20

1. Csapo A.I., Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. Obstet. Gynecol. Surv. 1978; 33: 69–81.

2. Nováková L, Blanková B. {0}VIII. Reproductive Systems. 1. Female Reproductive System, Pregnancy and Childbirth. В: Functions of Cells and Human Body. http://fblt.cz/en/skripta/viii-rozmnozovaci-soustavy/1-zenske-pohlavni-organy-tehotenstvi-a-porod/.

3. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8 (Suppl 1): 3–63.

4. Di Renzo G.C., Mattei A., Gojnic M., Gerli S. Прогестерон и беременность. Curr Opin Obstet Gynecol. 2005; 17(6): 598–600.

5. Griesinger G., Herman Tournaye, Nick Macklon, Felice Petraglia, Petra Arck, Christophe Blockee, Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction // RBMO. 2019. Vol. 38, Issue 2. P. 249–259.

6. Мedawar P.B. Nobel lecture 1960 г.: Immunological tolerance. Доступно на http://www.nobelprize.org/nobel_prizes/medicine/laureates/1960/medawar-lecture.html [Google Scholar].

7. Szekeres-Bartho J., Barakonyi A., Par G., Polgar B., Palkovics T., Szereday L. Progesterone as an immunomodulatory molecule. Int. Immunopharmacol. 2001; 1: 1037–1048.

8. Mao G., Wang J., Kang Y., Tai P., Wen J., Zou Q., Li G., Ouyang H., Xia G., Wang B. Progesterone increases systemic and local uterine proportions of CD4+CD25+ Treg cells during midterm pregnancy in mice. Endocrinology 2010; 151: 5477–5488. doi: 10.1210/en.2010-0426.

9. Engler J.B., Kursawe N., Solano M.E., Patas K., Wehrmann S., Heckmann N., Luhder F., Reichardt H.M., Arck P.C., Gold S.M., Friese M.A. Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy. Proc. Natl. Acad. Sci. U. S. A. 2017; 114: E181–E190. doi: 10.1073/pnas.1617115114.

10. Areia A., Vale-Pereira S., Alves V., Rodrigues-Santos P., Moura P., Mota-Pinto A. Membrane progesterone receptors in human regulatory T cells: a reality in pregnancy. BJOG. 2015; 122: 1544–1550. doi: 10.1111/1471-0528.13294.

11. Dosiou C., Hamilton A.E., Pang Y., Overgaard M.T., Tulac S., Dong J., Thomas P., Giudice L.C. Expression of membrane progesterone receptors on human T lymphocytes and jurkat cells and activation of G-proteins by progesterone. J. Endocrinol. 2008; 196: 67–77. doi: 10.1677/JOE-07-0317.

12. Blois S.M., Ilarregui J.M., Tometten M., Garcia M., Orsal A.S., Cordo-Russo R., Toscano M.A., Bianco G.A., Kobelt P., Handjiski B., Tirado I., Markert U.R., Klapp B.F., Poirier F., Szekeres-Bartho J., Rabinovich G.A., Arck P.C. A pivotal role for galectin-1 in fetomaternal tolerance. Nat. Med. 2007; 13: 1450–1457. doi: 10.1038/nm1680.

13. Griesinger G., Blockeel C., Sukhikh G.T., Patki A., Dhorepatil B., Yang D.Z., Chen Z.J., Kahler E., Pexman-Fieth C., Tournaye H. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in in vitro fertilization: a randomized clinical trial. Hum. Reprod. 2018; 33: 2212–2221. doi: 10.1093/humrep/dey306.

14. Krey G., Frank P., Shaikly V., Barrientos G., Cordo-Russo R., Ringel F., Moschansky P., Chernukhin I.V., Metodiev M., Fernandez N., Klapp B.F., Arck P.C., Blois S.M. In vivo dendritic cell depletion reduces breeding efficiency, affecting implantation and early placental development in mice. J. Mol. Med. (Berl.) 2008; 86: 999–1011. doi: 10.1007/s00109-008-0379-2.

15. Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е. Акушерство: национальное руководство. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2018. 1088 с.

16. ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. Human Reproduction Open. 2020: hoaa009. https://doi.org/10.1093/hropen/hoaa009 PMID: 32395637.

17. Practice Committee of the American Society for Reproductive Medicine. Current clinical irrelevance of luteal phase deficiency: a committee opinion. Fertil Steril 2015; 103: e27–e32.

18. Edwards R.G., Steptoe P.C., Purdy J.M. Establishing full-term human pregnancies using cleaving embryos grown in vitro. Br. J. Obstet. Gynaecol. 1980; 87: 737–756.

19. Fatemi H.M. Assessment of the luteal phase in stimulated and substituted cycles. Facts, views & vision in ObGyn. 2009; 1: 30–46.

20. Fauser B.C., Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol. Metab. 2003; 14: 236–242.

21. Barbosa M.W.P., Silva L.R., Navarro P.A. et al. Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2016; 48: 161–170.

22. Kolibianakis E.M., Venetis C.A., Papanikolaou E.G., Diedrich K., Tarlatzis B.C., Griesinger G. Estrogen addition to progesterone for luteal phase support in cycles stimulated with GnRH analogues and gonadotrophins for IVF: a systematic review and meta-analysis. Human Reprod. 2008; 23(6): 1346: 1354–710.

23. Macklon N.S., Fauser B.C. Impact of ovarian hyperstimulation on the luteal phase. J. Reprod. Fertil. Suppl. 2000; 55: 101–108.

24. IVF Worldwide. An updated survey: the use of progesterone for luteal phase support. Доступно по ссылке http://www.ivf-worldwide.com/survey/an-updated-survey-on-the-use-of-progesterone-for-luteal-phase-support-in-stimulated-ivf-cycles/results-an-updated-survey-on-the-use-of-progesterone-for-luteal-phase-support-in-stimulated-ivf-cycles.html.

25. ESHRE Early Pregnancy Guideline Development Group. Recurrent pregnancy loss: guideline of the European Society of Human Reproduction and Embryology. 2017.

26. Abbott Laboratories. Company Core Data Sheet. Dydrogesterone. 5 июля 2017 г.

27. Besins Healthcare (UK) Ltd. Utrogestan 100 mg oral capsules. Summary of Product Characteristics UK. 14 июля 2017 г.

28. Besins Healthcare (UK Ltd. Utrogestan vaginal 200 mg capsules. Summary of Product Characteristics UK. 29 June 2017.

29. Linden M., Buckingham K., Farquhar C. et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015: CD009154.

30. Czajkowski K., Sienko J., Mogilinski M., Bros M., Szczecina R., Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil. Steril. 2007; 87: 613–618. doi: 10.1016/j.fertnstert.2006.07.1506.

31. Guerra J.A., López-Muñoz F., Álamo C. Progestins in combined contraceptives. J Exp. Clin. Med. 2013; 5: 51–55. doi: 10.1016/j. jecm.2013.02.007.

32. Davar R., Farid Mojtahedi M., Miraj S. Effects of single dose GnRH agonist as luteal support on pregnancy outcome in frozen-thawed embryo transfer cycles: an RCT. Iran J Reprod Med. 2015; 13(8): 483: 488–710.

33. Yanushpolsky E.H. Luteal phase support in in vitro fertilization. Semin Reprod Med. 2015; 33(2): 118–127.

34. Tournaye H., Sukhikh G.T., Kahler E., Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017; 32(5): 1019–1027.

35. Vaisbuch E., Leong M., Shoham Z. Progesterone support in IVF: is evidence-based medicine translated to clinical practice? A worldwide web-based survey. Reprod Biomed Online. 2012; 25(2): 139–145.

36. Makhmudova G.M., Nazhmutdinova D.K., Gafarova D.K., Lukmanova Y.D. Efficacy of duphaston treatment in women with endometriosis after reconstructive surgery. Akush. Ginekol. (Sofiia). 2003; 42: 42–46.

37. Mirza F.G., Patki A., Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol. Endocrinol. 2016; 32: 97–106. doi: 10.3109/09513590.2015.1121982. Moszkowski E., Woodruff J.D., Jones G.E. The inadequate luteal phase. Am. J. Obstet. Gynecol. 1962; 83: 363–372.

38. Rižner T.L., Brožič P., Doucette C. et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011; 76(6): 607–615.

39. Schindler A.E., Campagnoli C., Druckmann R. et al. Classification and pharmacology of progestins. Maturitas. 2008; 61(1–2): 171–180.

40. Stanczyk F.Z., Hapgood J.P., Winer S. et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013; 34(2): 171–208; doi: 10.1210/er.2012-1008.

41. Abbott B.V. 8 June 2017. Duphaston 10, film-coated tablets 10 mg Summary of Product Characteristics.

42. Arvidsson C., Hellborg M., Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005; 123: 87–91. doi: 10.1016/j.ejogrb.2005.02.019.

43. Bingham J.S. Single blind comparison of ketoconazole 200 mg oral tablets and clotrimazole 100 mg vaginal tablets and 1% cream in treating acute vaginal candidosis. Br. J. Vener. Dis. 1984; 60: 175–177.

44. Chakravarty B.N., Shirazee H.H., Dam P., Goswami S.K., Chatterjee R., Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J. Steroid Biochem. Mol. Biol. 2005; 97: 416–420. doi: 10.1016/j.jsbmb.2005.08.012.

45. Patki A., Pawar V.C. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol. 2007; 23(Suppl 1): 68–72.

46. Paulson R.J., Collins M.G., Yankov V.I. Progesterone Pharmacokinetics and Pharmacodynamics With 3 Dosages and 2 Regimens of an Effervescent Micronized Progesterone Vaginal Insert. J Clin Endocrinol Metab. 2014; 99(11): 4241–4249.

47. Tavaniotou A., Smitz J., Bourgain C., Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update. 2000; 6(2): 139–148.

48. Reerink E.H., Scholer H.F., Westerhof P., Querido A., Kassenaar A.A., Diczfalusy E., Tillinger K.C. A new class of hormonally active steroids. Nature. 1960; 186: 168–169.

49. Zafardoust S., Jeddi-Tehrani M., Mehdi Akhondi M. et al. Effect of Administration of Single Dose GnRH Agonist in Luteal Phase on Outcome of ICSI-ET Cycles in Women with Previous History of IVF/ICSI Failure: A Randomized Controlled Trial. J Reprod Infertil. 2015; 16(2): 96–101.